ADI-PEG20 Clinical Trials

3 actively recruiting trials

▼ -1 trial since June 2026

Also known as: Pegargiminase, pegargiminase, pegylated arginine deiminase

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

Polaris Group2
Chang Gung Memorial Hospital1

Indications

Liver Disease3
Liver Cancer2
Hepatocellular Carcinoma2
Cancer2
Nonalcoholic Steatohepatitis (NASH)1

Other3 trials

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

Phase 2

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

Phase 3

Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.